Search Results - "Eder, J.P"

3098 Nivolumab (NIVO) monotherapy or in combination with ipilimumab (IPI) for treatment of recurrent small cell lung cancer (SCLC) by Calvo, E, López-Martin, J.A, Bendell, J, Eder, J.P, Taylor, M, Ott, P.A, Pietanza, M.C, Horn, L, Jäger, D, Braud, F. De, Morse, M.A, Ascierto, P.A, Le, D.T, Amin, A, Evans, J, Simon, J, Lin, C.S, Christensen, O, Antonia, S.J

Get full text

Safety and Clinical Activity of MK-3475 as Initial Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) by Balmanoukian, A.S, Rizvi, N.A, Garon, E.B, Patnaik, A, Gandhi, L, Leighl, N.B, Goldman, J.W, Eder, J.P, Johnson, E.A, Blumenschein, G.R, Gubens, M.A, Papadopoulos, K.P, Lubiniecki, G.M, Zhang, J, Niewood, M, Emancipator, K, Dolled-Filhart, M, Hanson, M.E, Hui, R

Get full text

488 A Combination of Surrogate and Tumor Biopsy Biomarker Data Demonstrates JAK Pathway Inhibition by AZD1480 in Phase I Patient Samples by McCoon, P, Eder, J.P, Huszar, D, McEachern, K, Schroeder, P, Tang, W, Womack, C, Kang, Y.K, Eckhardt, S.G

Get full text

127 Correlation of clinical activity of pembrolizumab (MK-3475) with immunohistochemical staining for programmed death-1 ligand (PD-L1) in ≥50% of tumor cells in a prospective non-small cell lung cancer (NSCLC) validation population by Garon, E.G, Rizvi, N.A, Leighl, N.B, Hui, R, Eder, J.P, Patnaik, A, Aggarwal, C, Horn, L, Balmanoukian, A.S, Gubens, M.A, Felip-Font, E, Costa, E. Carceny, Soria, J.C, Ahn, M.J, Arkenau, H.T, Lee, J.S, Robinet, G, Lubiniecki, G.M, Zhang, J, Emancipator, K, Rutledge, R, Dolled-Filhart, M, Gandhi, L

Get full text

Proteasome Inhibition With Bortezomib (PS-341): A Phase I Study With Pharmacodynamic End Points Using a Day 1 and Day 4 Schedule in a 14-Day Cycle by HAMILTON, A. L, EDER, J. P, KINCHLA, N, BOYDEN, J, YEE, H, ZELENIUCH-JACQUOTTE, A, WRIGHT, J, ELLIOTT, P, ADAMS, J, MUGGIA, F. M, PAVLICK, A. C, CLARK, J. W, LIEBES, L, GARCIA-CARBONERO, R, CHACHOUA, A, RYAN, D. P, SOMA, V, FARRELL, K

“…We performed a phase I study of a day (D) 1 and D4 bortezomib administration once every 2 weeks to determine the recommended phase II dose and toxicity…”
Get full text

BET inhibitors: a novel epigenetic approach by Doroshow, D.B., Eder, J.P., LoRusso, P.M.

“…Epigenetics has been defined as ‘the structural adaptation of chromosomal regions so as to register, signal or perpetuate altered activity states.’ Currently,…”
Get full text

Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial by Hui, R., Garon, E.B., Goldman, J.W., Leighl, N.B., Hellmann, M.D., Patnaik, A., Gandhi, L., Eder, J.P., Ahn, M.-J., Horn, L., Felip, E., Carcereny, E., Rangwala, R., Lubiniecki, G.M., Zhang, J., Emancipator, K., Roach, C., Rizvi, N.A.

“…Pembrolizumab improved survival as first- and second-line therapy compared with chemotherapy in patients with highly programmed death ligand 1 (PD-L1)…”
Get full text

CBX-12-101: A first-in-human study of CBX-12, an alphalex peptide drug conjugate (PDC) in patients with advanced or metastatic solid tumors by Meric-Bernstam, F., Eder, J.P., Vandross, A., Gara, M., Gayle, S., Pearson, P., DeCillis, A., Tolcher, A.

Get full text

1079TiP A phase I first-in-human study of PRTH-101, an IgG1 monoclonal antibody targeting DDR1, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies by Sen, S., Spira, A.I., Sommerhalder, D., Meric-Bernstam, F., Subbiah, V., Berlin, J.D., Parikh, A., Cecchini, M., Sanborn, R.E., Chablani, P.V., Peoples, G.E., Schürpf, T., Dillon, L.A., Clifton, G.T., Eder, J.P., Tolcher, A.W.

Get full text

1027TiP A phase Ib study of CM24 in combination with nivolumab in adults with advanced solid tumors, followed by a phase IIa study of CM24 in combination with nivolumab in NSCLC, and in combination with nivolumab and nab-paclitaxel in pancreatic cancer by Borazanci, E., Al Hallak, M.N., Eder, J.P., Golan, T., Pant, S., Perets, R., Markel, G., Schickler, M., Reuveni, H., Jin, L., Liang, B.

Get full text

1669P Monitoring immune checkpoint inhibition in advanced solid tumors using genome-wide cfDNA fragmentomes by Medina, J.E., Roussos Torres, E.T., Leal, A., Adleff, V., Lumbard, K., Keefer, L., Carey, J., Brufsky, A., Lorusso, P., Eder, J.P., Chung, V., Downs, M., O'Connor, A., Piekarz, R., Streicher, H., Jaffee, E.M., Scharpf, R.B., Stearns, V., Connolly, R.M., Velculescu, V.E.

Get full text

964MO Entinostat, nivolumab and ipilimumab in advanced HER2-negative breast cancer (ETCTN-9844) by Roussos Torres, E.T., Leatherman, J., Rafie, C., Brufsky, A., Lorusso, P., Eder, J.P., Chung, V., Yuan, Y., Downs, M., O’Connor, A., Piekarz, R., Streicher, H., Rudek, M.A., Zhu, Q., Fertig, E., Anders, R.A., Cimino-Mathews, A., Jaffee, E.M., Stearns, V., Connolly, R.M.

Get full text

Molecular cloning and identification of a point mutation in the topoisomerase II cDNA from an etoposide-resistant Chinese hamster ovary cell line by CHAN, V. T. W, SHU-WING NG, EDER, J. P, SCHNIPPER, L. E

“…Topoisomerase II (Top II) is the target enzyme for many antineoplastic drugs such as epipodophyllotoxins, anthracyclines, and acridines. Cell lines with…”
Get full text

A Phase 1 first-in-human study of MEDI0680, an anti-PD-1 monoclonal antibody (mAb) in adult patients (pts) with advanced tumors by Naing, A., Goel, S., Curti, B., Weise, A., Eder, J.P., Marshall, S., Morehouse, C., Li, X., Karakunnel, J.J., Infante, J.

Get full text

Pharmacokinetics (PK) and pharmacodynamics (PD) of a novel carcinoembryonic antigen (CEA) T-cell bispecific antibody (CEA-CD3 TCB) for the treatment of CEA-positive solid tumors by Melero, I., Segal, N.H., Saro, J., Ros, W., Martinez-Garcia, M., Argiles, G., Moreno, V., Ponce, S., Marabelle, A., Cleary, J.M., Hurwitz, H.I., Eder, J.P., Jamois, C., Andersson, E., Bouseida, S., Sandoval, F., Bacac, M., Nayak, T., Karanikas, V., Calvo, E.

Get full text

First-in-human study of the monopolar spindle 1 (Mps1) kinase inhibitor BAY 1161909 in combination with paclitaxel in subjects with advanced malignancies by Lorusso, P, Chawla, S P, Bendell, J, Shields, A F, Shapiro, G, Rajagopalan, P, Cyris, C, Bruns, I, Mei, J, Souza, F, Rasco, D, Eder, J P, Tolcher, A W

Get full text

Automatic Personalisation of Study Guides in Flipped Classroom: A Case Study in a Distributed Systems Course by Araujo, Pedro, Costa, Cecilia, Viana, Windson, de Lima Veras, Necio, Farias, Eder J. P.

“…In Computer Science programs, teaching the subject of Distributed Systems (DS) presents many challenges, especially related to the students' prior knowledge…”
Get full text

Phase I studies of the novel carcinoembryonic antigen T-cell bispecific (CEA-CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients (pts) with metastatic colorectal cancer (mCRC) by Segal, N.H., Saro, J., Melero, I., Ros, W., Argiles, G., Marabelle, A., Rodriguez Ruiz, M.E., Albanell, J., Calvo, E., Moreno, V., Cleary, J.M., Eder, J.P., Karanikas, V., Bouseida, S., Sandoval, F., Sabanes, D., Sreckovic, S., Hurwitz, H.I., Paz-Ares, L., Tabernero, J.

Get full text

Phase 1/2 study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032 by Antonia, S.J., Bendell, J., Taylor, M., Calvo, E., Jäger, D., de Braud, F., Ott, P.A., Pietanza, M.C., Horn, L., Le, D.T., Morse, M.A., López-Martin, J.A., Ascierto, P.A., Christensen, O., Grosso, J.F., Simon, J., Lin, C., Eder, J.P.

Get full text

A phase I study evaluating DLYE5953A, an antibody-drug conjugate targeting the tumor-associated antigen lymphocyte antigen 6 complex locus E (Ly6E), in patients (Pts) with solid tumors by Modi, S., Eder, J.P., Lorusso, P., Weekes, C., Chandarlapaty, S., Tolaney, S.M., McLaughlin, J., Camidge, D.R., Chang, C.-W., Nazzal, D., Chen, S.-C., Schuth, E., Brunstein, F., Darbonne, W., Flanagan, W., Ungewickell, A., Shapiro, G.

Get full text